Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well selumetinib works in treating patients with
papillary thyroid cancer that did not respond to radioactive iodine. Selumetinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.